Compass Therapeutics, Inc.(CMPX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMPX Compass Therapeutics, Inc.

Trading 03-18 10:06:44 EDT

5.29

-0.16

-2.94%

High5.41	Low5.27	Vol110.76K
Open5.41	D1 Closing5.45	Amplitude2.63%
Mkt Cap952.67M	Tradable Cap629.51M	Total Shares180.09M
T/O591.07K	T/O Rate0.09%	Tradable Shares119.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMPX","market":"US","secType":"STK","nameCN":"Compass Therapeutics, Inc.","latestPrice":5.29,"timestamp":1773842799831,"preClose":5.45,"halted":0,"volume":110760,"delay":0,"changeRate":-0.02935779816513764,"floatShares":119000000,"shares":180087915,"eps":-0.42163,"marketStatus":"Trading","change":-0.16,"latestTime":"03-18 10:06:44 EDT","open":5.41,"high":5.41,"low":5.2669,"amount":591070.917216,"amplitude":0.026257,"askPrice":5.3,"askSize":338,"bidPrice":5.28,"bidSize":196,"shortable":3,"etf":0,"ttmEps":-0.42163,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773864000000},"marketStatusCode":2,"adr":0,"listingDate":1605243600000,"exchange":"NASDAQ","adjPreClose":5.45,"preHourTrading":{"tag":"盘前","latestPrice":5.4103,"preClose":5.45,"latestTime":"09:28 EDT","volume":1012,"amount":5542.363728,"timestamp":1773840488379,"change":-0.0397,"changeRate":-0.007284,"amplitude":0.019303},"postHourTrading":{"tag":"盘后","latestPrice":5.5398,"preClose":5.45,"latestTime":"19:53 EDT","volume":117803,"amount":642161.28,"timestamp":1773791621897,"change":0.0898,"changeRate":0.016477,"amplitude":0.016514},"volumeRatio":0.728231,"impliedVol":3.8747,"impliedVolPercentile":0.9761},"requestUrl":"/m/hq/s/CMPX/wiki","defaultTab":"wiki","newsList":[{"id":"2617368636","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Silence Therapeutics (SLN), RxSight (RXST) and Compass Therapeutics (CMPX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617368636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617368636?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:40","pubTimestamp":1772808059,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Silence Therapeutics (SLN – Research Report), RxSight (RXST – Res...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-silence-therapeutics-sln-rxsight-rxst-and-compass-therapeutics-cmpx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-silence-therapeutics-sln-rxsight-rxst-and-compass-therapeutics-cmpx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4539","SLN","HCSG","CMPX","LU0029874061.USD","LU0128526141.USD","BK4588","RXST","BK4198","BK4581","BK4137","BK4139","XLV","BK4585","XBI"],"gpt_icon":0},{"id":"2617682054","title":"Guggenheim Keeps Their Buy Rating on Compass Therapeutics (CMPX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617682054","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617682054?lang=en_us&edition=fundamental","pubTime":"2026-03-06 19:59","pubTimestamp":1772798350,"startTime":"0","endTime":"0","summary":"Guggenheim analyst maintained a Buy rating on Compass Therapeutics today and set a price target of $12.00. In addition to Guggenheim, Compass Thera...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-compass-therapeutics-cmpx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-compass-therapeutics-cmpx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPX"],"gpt_icon":0},{"id":"2617568521","title":"Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Compass Therapeutics (CMPX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617568521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617568521?lang=en_us&edition=fundamental","pubTime":"2026-03-05 23:50","pubTimestamp":1772725807,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PepGen Inc. (PEPG – Research Report) and Compass The...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pepgen-inc-pepg-and-compass-therapeutics-cmpx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pepgen-inc-pepg-and-compass-therapeutics-cmpx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4581","BK4588","BK4137","XBI","BK4585","HCSG","BK4139","CMPX","XLV","PEPG","LU0029874061.USD","LABU"],"gpt_icon":0},{"id":"2617542762","title":"Compass Therapeutics' Q4 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2617542762","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617542762?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:55","pubTimestamp":1772715334,"startTime":"0","endTime":"0","summary":"Compass Therapeutics  reported a Q4 net loss Thursday of $0.09 per diluted share, narrower than a loss of $0.11 a year earlier.Analysts polled by FactSet expected a loss of $0.08.As expected, no revenue for the quarter ended Dec. 31 was reported.As of Dec. 31, the company said it had $209 million in cash and marketable securities, which will likely finance operations into 2028.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMPX","BK4139"],"gpt_icon":0},{"id":"2617454267","title":"Compass Therapeutics reports Q4 EPS (9c), consensus (9c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617454267","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617454267?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:38","pubTimestamp":1772714282,"startTime":"0","endTime":"0","summary":"“2025 marked a year of significant progress for Compass, highlighted by our lead asset tovecimig successfully meeting the primary endpoint of overa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/compass-therapeutics-reports-q4-eps-9c-consensus-9c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/compass-therapeutics-reports-q4-eps-9c-consensus-9c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPX"],"gpt_icon":0},{"id":"2617542828","title":"Earnings Flash (CMPX) Compass Therapeutics Posts Q4 Net Loss $0.09 a Share, vs. FactSet Est of $0.09 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2617542828","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617542828?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:37","pubTimestamp":1772714261,"startTime":"0","endTime":"0","summary":"Earnings Flash (CMPX) Compass Therapeutics Posts Q4 Net Loss $0.09 a Share, vs. FactSet Est of $0.09 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMPX"],"gpt_icon":0},{"id":"2617802542","title":"Compass Therapeutics Q4 EPS $(0.09) Beats $(0.10) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617802542","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617802542?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:36","pubTimestamp":1772714205,"startTime":"0","endTime":"0","summary":"Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 12.62 percent. This is a 18.18 percent increase over losses of $(0.11) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51062884/compass-therapeutics-q4-eps-0-09-beats-0-10-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPX"],"gpt_icon":0},{"id":"2617298544","title":"Compass Therapeutics posts FY 2025 R&D expenses of USD 56.0 million, up 32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617298544","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617298544?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:30","pubTimestamp":1772713820,"startTime":"0","endTime":"0","summary":"Compass Therapeutics reported a FY 2025 net loss of USD 66.5 million and a net loss per share of USD 0.42. R&D expenses rose 32% to USD 56.0 million, while G&A expenses increased 12% to USD 16.9 million. The company ended FY 2025 with USD 209 million in cash and marketable securities, which it expects will fund operations into 2028. On the pipeline, Compass Therapeutics said the prespecified 80% overall survival event threshold was reached in Q1 2026 in the Phase 2/3 COMPANION-002 study of tovecimig in biliary tract cancer, with progression-free survival and overall survival analyses expected to be reported in April. For CTX-8371, expansion cohorts are open in triple-negative breast cancer  and non-small cell lung cancer , with an additional Hodgkin lymphoma cohort  expected to begin shortly; initial expansion data are expected at a major medical conference in Q2 2026. The FDA cleared the IND for CTX-10726, with a Phase 1 study expected to open for enrollment in Q1 2026, and the compan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL5XPRQH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999014021.USD","SG9999014039.USD","SG9999014013.SGD","CMPX","LU0314104364.USD","NDAQ","LU2095319765.USD","SG9999014005.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4112","BK4585","LU2210149790.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2617441205","title":"Compass Therapeutics Q4 Income From Operations USD -17.99 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617441205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617441205?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:30","pubTimestamp":1772713800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nPLX145E35:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPX","BK4139"],"gpt_icon":0},{"id":"2617544436","title":"Press Release: Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2617544436","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617544436?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:30","pubTimestamp":1772713800,"startTime":"0","endTime":"0","summary":"-- In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A. bispecific antibody) in patients with biliary tract cancer, the. prespecified event threshold of 80% overall survival  events was. reached in Q1 2026; as a result, the analyses of progression-free. survival  and OS are expected to be reported in April.-- Based on previously reported responses in patients with triple-negative. breast cancer  and non-small cell lung cancer  in the Phase. are now open and enrolling patients with these tumor types; based on an. additional response in a patient with Hodgkin lymphoma, a further. \"Our novel PD-1 x PD-L1 checkpoint inhibitor, CTX-8371, also demonstrated strong clinical activity this past year, with three robust responses in patients with both solid tumors and hematologic malignancies, all observed in heavily pre-treated patients who received prior checkpoint inhibitor therapies. We also continued to advance our other clinical-stage assets, CTX-471 and CTX-10726.\". \"2026 is po","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4210","LU0345780281.USD","PFS","BK4211","BK4097","CMPX","BK4195","OS","BK4139","LU0345780521.USD","BK4570","HL"],"gpt_icon":0},{"id":"2614832984","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2614832984","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614832984?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:00","pubTimestamp":1772190000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Arbor Realty Tr                                  4Q       .13   8:30 AM. ·Delek US Hldgs                                    4Q      (.19)  7:00 AM. ·NW Natural Hldg                                  4Q      1.36   6:00 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALXO","ACHR","ATRA","BBY","ASTH","BRK.B","ANTA","ACEL","ABR","NPCE","BTSG","AMWD","AAON","AMRX","AMLX","CRI","AZO","ANIP","CVEO","CRC","CRD.A","CERS","AMR","CORZ","CRD.B","ARCT","AMRC","CGEN","GSAT","BRCB","CRCT","BLTE","BCYC","BRK.A","STNE","CMPX","BEEP","ACRS","ADT","ASAN","BGS","CLMT","ALG","CXDO","LIF","BOX"],"gpt_icon":1},{"id":"2613870777","title":"Compass Therapeutics Inc.  expected to post a loss of 9 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2613870777","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613870777?lang=en_us&edition=fundamental","pubTime":"2026-02-23 22:09","pubTimestamp":1771855750,"startTime":"0","endTime":"0","summary":"Compass Therapeutics Inc.  expected to post a loss of9cents a share - Earnings Preview Compass Therapeutics Inc. CMPX.OQ CMPX.O is expected to  show no change in quarterly revenue when it reports  res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL8N3ZJ1BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPX","BK4139"],"gpt_icon":0},{"id":"2613629577","title":"Compass Therapeutics Moves CTX-10726 Into the Clinic: What Early Investors Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2613629577","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613629577?lang=en_us&edition=fundamental","pubTime":"2026-02-21 00:35","pubTimestamp":1771605354,"startTime":"0","endTime":"0","summary":"Compass Therapeutics, Inc. ($CMPX) announced an update on their ongoing clinical study. The Phase 1 study “A Phase 1, Open-Label, Multiple-Ascendin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/compass-therapeutics-moves-ctx-10726-into-the-clinic-what-early-investors-should-know?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/compass-therapeutics-moves-ctx-10726-into-the-clinic-what-early-investors-should-know?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","CMPX","BK4211","BK4139"],"gpt_icon":0},{"id":"2611087168","title":"Craig-Hallum bullish on Compass Therapeutics, initiates with a Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2611087168","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611087168?lang=en_us&edition=fundamental","pubTime":"2026-02-13 22:16","pubTimestamp":1770992169,"startTime":"0","endTime":"0","summary":"As previously reported, Craig-Hallum initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $15 price target The firm says Compass...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/craig-hallum-bullish-on-compass-therapeutics-initiates-with-a-buy-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/craig-hallum-bullish-on-compass-therapeutics-initiates-with-a-buy-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CMPX"],"gpt_icon":0},{"id":"2606715316","title":"Analysts Offer Insights on Healthcare Companies: Teleflex (TFX) and Compass Therapeutics (CMPX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606715316","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606715316?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:00","pubTimestamp":1769601622,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teleflex (TFX – Research Report) and Compass Therapeutics (CMPX –...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-teleflex-tfx-and-compass-therapeutics-cmpx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-teleflex-tfx-and-compass-therapeutics-cmpx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","XLV","TFX","BK4581","CMPX","XBI","BK4139","BK4588","LU0128526141.USD","LU0029874061.USD","BK4137","BK4585","HCSG","BK4504","LABU"],"gpt_icon":0},{"id":"2604948182","title":"Assessing Compass Therapeutics (CMPX) Valuation After A Year Of Strong Share Price Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2604948182","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604948182?lang=en_us&edition=fundamental","pubTime":"2026-01-17 08:34","pubTimestamp":1768610086,"startTime":"0","endTime":"0","summary":"Why Compass Therapeutics Is On Investors’ Radar\nCompass Therapeutics (CMPX) has drawn attention after recent share price moves, with the stock showing double digit returns over the past month and past 3 months despite reporting a net loss and no revenue.\nSee our latest analysis for Compass Therapeutics.\nAt a share price of $5.70, Compass Therapeutics has a 30 day share price return of 14.92% and a 90 day share price return of 33.80%. Its 1 year total shareholder return of 119.23% suggests...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmpx/compass-therapeutics/news/assessing-compass-therapeutics-cmpx-valuation-after-a-year-o","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmpx/compass-therapeutics/news/assessing-compass-therapeutics-cmpx-valuation-after-a-year-o","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","DCF","CMPX"],"gpt_icon":0},{"id":"2603937933","title":"Will Compass Therapeutics’ (CMPX) New Oncology Leaders Redefine Its Path From Pipeline to Commercial Scale?","url":"https://stock-news.laohu8.com/highlight/detail?id=2603937933","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603937933?lang=en_us&edition=fundamental","pubTime":"2026-01-16 00:18","pubTimestamp":1768493897,"startTime":"0","endTime":"0","summary":"Compass Therapeutics has appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer, with both roles effective January 1, 2026, adding experienced oncology leadership across commercial and clinical development functions.\nThese hires bring deep experience in successful oncology drug launches and advancing immuno-oncology programs through pivotal trials and regulatory approvals, potentially strengthening Compass Therapeutics’ execution capabilities.\nNext,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmpx/compass-therapeutics/news/will-compass-therapeutics-cmpx-new-oncology-leaders-redefine","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmpx/compass-therapeutics/news/will-compass-therapeutics-cmpx-new-oncology-leaders-redefine","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CMPX","BK4139"],"gpt_icon":0},{"id":"2602533444","title":"Compass Therapeutics: Strengthening Clinical Pipeline and 2026 Milestones Underscore Buy Rating and Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2602533444","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602533444?lang=en_us&edition=fundamental","pubTime":"2026-01-11 01:55","pubTimestamp":1768067720,"startTime":"0","endTime":"0","summary":"Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Compass Therapeutics. The associated price target was raised to $12.00. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/compass-therapeutics-strengthening-clinical-pipeline-and-2026-milestones-underscore-buy-rating-and-upside-potential-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/compass-therapeutics-strengthening-clinical-pipeline-and-2026-milestones-underscore-buy-rating-and-upside-potential-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPX"],"gpt_icon":0},{"id":"2601361541","title":"Compass Therapeutics (CMPX) Gets a Buy from Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2601361541","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601361541?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:39","pubTimestamp":1767875952,"startTime":"0","endTime":"0","summary":"In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Compass Therapeutics, with a price target of $10.00. Acco...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/compass-therapeutics-cmpx-gets-a-buy-from-canaccord-genuity-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/compass-therapeutics-cmpx-gets-a-buy-from-canaccord-genuity-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPX","BK4139"],"gpt_icon":0},{"id":"2601381513","title":"Compass Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601381513","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601381513?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:49","pubTimestamp":1767710940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 09:49 ET (14:49 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.compasstherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":-0.1322},{"period":"3month","weight":0.0988},{"period":"6month","weight":0.481},{"period":"1year","weight":1.3191},{"period":"ytd","weight":0.0149}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0161},{"period":"3month","weight":-0.0009},{"period":"6month","weight":0.0129},{"period":"1year","weight":0.1827},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.118622},{"month":2,"riseRate":0.4,"avgChangeRate":0.052033},{"month":3,"riseRate":0.2,"avgChangeRate":-0.146038},{"month":4,"riseRate":0.25,"avgChangeRate":-0.07325},{"month":5,"riseRate":0.4,"avgChangeRate":0.146493},{"month":6,"riseRate":0.6,"avgChangeRate":0.008734},{"month":7,"riseRate":0.6,"avgChangeRate":0.017507},{"month":8,"riseRate":0.6,"avgChangeRate":0.058578},{"month":9,"riseRate":0.4,"avgChangeRate":-0.036741},{"month":10,"riseRate":0.4,"avgChangeRate":0.029035},{"month":11,"riseRate":0.6,"avgChangeRate":0.162335},{"month":12,"riseRate":0.2,"avgChangeRate":-0.003054}],"exchange":"NASDAQ","name":"Compass Therapeutics, Inc.","nameEN":"Compass Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Compass Therapeutics, Inc.(CMPX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Compass Therapeutics, Inc.(CMPX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Compass Therapeutics, Inc.,CMPX,Compass Therapeutics, Inc.股票,Compass Therapeutics, Inc.股票老虎,Compass Therapeutics, Inc.股票老虎国际,Compass Therapeutics, Inc.行情,Compass Therapeutics, Inc.股票行情,Compass Therapeutics, Inc.股价,Compass Therapeutics, Inc.股市,Compass Therapeutics, Inc.股票价格,Compass Therapeutics, Inc.股票交易,Compass Therapeutics, Inc.股票购买,Compass Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Compass Therapeutics, Inc.(CMPX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Compass Therapeutics, Inc.(CMPX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction